Clinuvel Announces Positive Results of First Phase II US Study of SCENESSE® in Orphan Disease Erythropoietic Protoporphyria (EPP)
BAAR, Switzerland & MELBOURNE, Australia--(BUSINESS WIRE)--Clinuvel Pharmaceuticals Limited (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY), a global biopharmaceutical company with unique expertise on the interaction of light and human skin, today announced positive results of its first US Phase II study of the novel photoprotective drug afamelanotide, known as SCENESSE®.